STAT@ASH: From Sickle Cell to Cancer

About

With discussion about everything from the withdrawal of the sickle cell drug Oxbryta to the promises of cutting-edge cancer research, the American Society of Hematology’s meeting will be a focal point for physicians and drug developers alike.

Join us for an evening of lively discussions and networking — drinks and light bites will be served.

Please note: This event will start at 6 p.m. PT.

Register Now

Explore the Agenda

6:00 – 6:45 p.m. PT | Arrival & Registration

Drinks and light bites will be served. 

6:45 – 6:50 p.m. PT | Opening from STAT

• Nicholas St. Fleur, general assignment reporter; associate editorial director of events, STAT 

6:50 – 6:55 p.m. PT | Spotlight on Blood Cancer: Measuring Progress and Accelerating Innovation | Sponsor Session

Breakthroughs don’t happen in a single lab, organization or institution—they evolve, from early ideas to approved therapies. For 75 years, The Leukemia & Lymphoma Society has been supporting every stage of research. Now, a bold goal for the future: to save another million years of patient life, in aggregate. Here is the plan.

• E. Anders Kolb, M.D., president and CEO, The Leukemia & Lymphoma Society

6:55 – 7:25 p.m. PT | Sickle Cell at a Crossroads

The first gene-editing treatments for sickle cell, including one powered by CRISPR, seemed to offer huge hope. But adoption has been slowed. Now what had looked like an effective medicine for the disease has been withdrawn. Join us for an expert panel on where the field is headed next.

• Titilope Fasipe, M.D., Ph.D., co-director, Sickle Cell & Thalassemia Program, Texas Children’s Hospital; assistant professor, Division Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine
• Julie Kanter, M.D., professor of medicine and pediatrics, The University of Alabama at Birmingham School of Medicine; president, National Alliance of Sickle Cell Centers (NASCC)
• Teonna Woolford, co-founder & CEO, Sickle Cell Reproductive Health Education Directive 
• Adam Feuerstein, senior writer, biotech, STAT (moderator)

7:25 – 7:35 p.m. PT | Unlocking the Potential and Promise of Precision Medicine in Cancer Care | Sponsor Session

The precision medicine revolution has dramatically improved the outlook for people with mutation-driven cancers, yet too often patients still don’t get these life-saving therapies, especially in rural and under-served communities. Streamlined workflows, comprehensive education programs, and data-driven insights can ensure that the right patient is offered the right therapy at the right time, regardless of where they live.

• John M. Burke, M.D., blood cancer specialist, Rocky Mountain Cancer Centers
• Devon Womack, president, The US Oncology Network
• Nicholas St. Fleur, general assignment reporter; associate editorial director of events, STAT (moderator)

7:35 – 8:05 p.m. PT | The Future of Blood Cancer Drugs

New technologies – bispecific antibodies, antibody-drug conjugates, and precision medicines – are reshaping the way hematological cancers are treated. Hear executives at the forefront of drug development discuss how these technologies are fueling a new era in cancer and beyond.

• Hesham Ahmed Abdullah, M.D., senior vice president, global head oncology, research & development, GSK
• Susan Galbraith, Ph.D., executive vice-president, oncology R&D, AstraZeneca
• Andres Sirulnik, M.D., Ph.D., SVP, hematology clinical development unit head, Regeneron
• Mark Wildgust, Ph.D., global vice president of oncology medical affairs, Johnson & Johnson Innovative Medicine
• Jonathan Wosen, Ph.D., West Coast biotech & life sciences reporter, STAT (moderator)

8:05 – 8:10 p.m. PT | In the Era of Targeted Therapies, What Do Blood Cancer Patients Really Want? | Sponsor Session

Targeted therapies have extended survival and improved quality of life for patients with certain types of blood cancers. As patients expect more from their treatment options, which factors are most crucial to them? Join us for a discussion about what matters most to patients and the innovations that could enable healthcare providers to better address their needs.

• Mehrdad Mobasher, M.D., M.P.H., chief medical officer, hematology, BeiGene

8:10 – 8:15 p.m. PT | Closing from STAT

8:15 – 9:00 p.m. PT | Networking Reception

Drinks and light bites will be served

Registration is still available! Click the button below to join us in person – please ignore the “watch on demand” indication.